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Introduction
Tumor cells contain nonsynonymous somatic mutations that alter the amino acid sequences of the proteins encoded by the affected genes (1) . Those alterations are foreign to the immune system and may therefore represent tumor-specific neoantigens capable of inducing anti-tumor immune responses (2, 3) . Somatic mutational and neoantigen density has recently been shown to correlate with long-term benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC) (4) and melanoma (5, 6) suggesting that a high density of neoepitopes stemming from somatic mutations may enhance clinical benefit from blockade of immune checkpoints that unleash endogenous responses to these mutation-associated neoantigens (MANAs). Expression of the programmed cell death ligand 1 (PD-L1) in tumors or tumorinfiltrating immune cells has been associated with responses to PD-1 blockade (7-9), however PD-L1 expression or other immune biomarkers have not been sufficient to fully explain therapeutic outcomes (10) .
Among the patients that initially respond to PD-1 blockade, some become resistant to the therapy (11) . Up-regulation of alternate immune checkpoints (12) , loss of HLA haplotypes (13) or somatic mutations in HLA or JAK1/JAK2 genes (14, 15) have been proposed as mechanisms of evasion to immune recognition in some patients, but the mechanisms underlying response and acquired resistance to immune checkpoint blockade have remained elusive. To examine mechanisms of resistance to immunotherapy, we performed genome-wide sequence analysis of protein coding genes and T cell receptor (TCR) clonotype analysis, followed by functional assays of autologous T cell activation of patients that demonstrated initial response to immune checkpoint blockade but ultimately developed progressive disease. These analyses identified immunogenic MANAs that were lost in the resistant tumors either through tumor cell elimination or chromosomal deletions, suggesting novel mechanisms for acquisition of resistance to immune checkpoint blockade. 
Results
Of a cohort of 42 NSCLC patients treated with single agent PD-1 or combined PD-1 and CTLA4
blockade, we identified all consecutive cases (n=4) that developed acquired resistance and where paired tumor specimens were available both before and after therapy (Supplementary Figures S1-S4 ). To examine the landscape of genomic alterations and associated neoantigens, we performed whole exome sequencing of tumors from these patients (Figure 1 , Supplementary Tables S1, S2). Pre-treatment and post-progression specimens were obtained from the same anatomic location (CGLU117) or from sites in close anatomic proximity (CGLU116, CGLU127 and CGLU161; Supplementary Figures S1-S3 ). Clinical and pathological characteristics for all patients are summarized in Supplementary Table S1 and described in detail in the Methods.
We used a high-sensitivity mutation detection pipeline (16) to identify 129, 302, 344 and 127 somatic sequence alterations in pre-immunotherapy tumor samples from patients CGLU116, CGLU117, CGLU127 and CGLU161, respectively. The number and type of alterations as well as specific driver genes identified, including TP53, KRAS, MYC, ARID1A, RB1, and SMARCA4 genes, were consistent with previous observations of sequence and copy number changes in NSCLC (17, 18) (Supplementary Tables S3, S4 ). Post-progression tumor samples revealed a change in the overall somatic sequence alterations, including both gains and losses resulting in 177, 323, 354 and 142 somatic sequence alterations for CGLU116, CGLU117, CGLU127 and CGLU161 respectively (Supplementary Tables S3, S4) .
We examined multiple immune-related parameters of peptides stemming from somatic alterations using a computational multi-dimensional neoantigen prediction platform (see Methods). This approach allowed for identification of peptides within mutated genes that were predicted to be processed and presented by major histocompatibility complex (MHC) class I proteins and therefore had the potential to elicit an immune response. The algorithm evaluated 6 material was limited and did not allow for both genomic and expression analyses. We identified 106, 240, 316 and 102 candidate mutation associated neoantigens (cMANAs) for pre-treatment tumors for CGLU116, CGLU117, CGLU127 and CGLU161, respectively. At the time of resistance to immune checkpoint blockade we identified 144, 250, 326 and 119 cMANAs from tumors of patients CGLU116, CGLU117, CGLU127 and CGLU161 (Supplementary Table S5 ).
As higher mutational load in resistant tumors was not consistent with the notion that a high mutation burden confers response to immune checkpoint blockade, we investigated whether the gained genomic alterations were enriched for mutations that are not associated with neoantigens. Interestingly, a higher fraction of mutations not encoding for neoantigens was identified among gained compared to eliminated mutations (19% versus 8%), however the small number of observations did not allow for statistical significance. This observation may suggest that the gained mutations were less likely to be related to an anti-tumor immune response. We also evaluated the gained alterations observed in the tumor samples to see if they may provide insight into known potential mechanisms of immunotherapy resistance (12) (13) (14) (15) 19) . However, there were no new alterations or copy number changes in post-therapy samples in the CD274 gene encoding for PD-L1, PDCD1 encoding for PD-1, CTLA4 or JAK1 or JAK2 genes. Similarly, we did not identify any genomic alterations in HLA genes, beta 2 microglobulin or other antigen presentation associated genes.
We observed that a subset of cMANAs present in the original tumors were eliminated in tumors at the time of resistance to immune checkpoint blockade (Figures 2A-B, 3A-I, and   Supplementary Table S6 ). This included 18, 10, 7, and 6 cMANAs that were not present in tumors at the time of acquired resistance for patients CGLU116, CGLU117, CGLU127 and CGLU161, respectively ( Figure 2 ). All eliminated cMANAs stemmed from single-base substitutions with the exception of neopeptides generated by a frameshift mutation in PCSK4 for CGLU116. Among the neoantigens with predicted MHC binding affinity <50 nM, the eliminated cMANAs had higher predicted MHC binding affinity than either those that were retained or gained in the resistant tumors (14.5 nM for lost neoantigens vs 23.4 nM or 24.7 nM for retained or gained neoantigens, respectively, p<0.05). The mutations in 23 eliminated cMANAs were found in positions thought to be important for TCR binding (20) , and are likely to be important for recognition of the mutant peptide especially when the wild type peptide is also presented (21) . A quarter of the eliminated cMANAs harbored mutations in either anchor or auxiliary anchor residues, presumably affecting MHC binding of these neoantigens (Supplementary Table S6 ).
While algorithm-based predictions of antigenicity are valuable in narrowing down the large number of peptides capable of being generated by a mutation to a set of potential antigenic peptides presented by self-MHC alleles, functional T cell recognition is critical to evaluate immune responsiveness. To this end, we developed a sensitive approach for assessing T cell response to cMANAs that utilized next-generation sequencing of TCR-Vb CDR3 regions as a measure of T cell clonality. In this approach, TCR-Vb clonality is compared pre-stimulation to post-stimulation in vitro with cMANA peptides. In addition to being more sensitive than the conventional enzyme linked immunospot assay, this technique allowed us to match cMANA expanded TCR-Vb CDR3s with those found in the patients' tumors themselves, identified by TCR-Vb CDR3 deep sequencing from the same DNA used for mutational analysis. Thus, this approach evaluates MANA-specific responses by T cells known to be present within the tumor microenvironment.
To evaluate T cell recognition of eliminated neoantigens, purified peripheral blood T cells from patients CGLU116, CGLU127 and CGLU161 were stimulated with autologous peripheral blood mononuclear cells (PBMCs) loaded with cMANA peptides in a 10-day culture system. We subsequently used TCR next generation sequencing to assess the differential abundance of neoantigen-specific T cell clonotypes in these expanded T cell populations. In order to further investigate the importance of eliminated cMANAs, we generated peptides from retained and gained cMANAs and assessed their potential to elicit a MANA-specific T cell expansion in samples where additional PBMCs were available (Figure 4A-D, Supplementary Table S7) .
For patient CGLU116, all eliminated cMANA peptides tested induced a clonal T cell expansion.
Peptides encoding for mutations in PGPA1
903Y>F and SLC26A7 117R>Q elicited a neoantigen-specific clonal T cell expansion with no reactivity observed against the wild-type peptides ( Figure 4B -C, Supplementary Figure   S6 , Supplementary Table S8 ). In contrast, none of the seven retained cMANA peptides for CGLU127 and CGLU161 were found to be immunogenic by our assay, while for case CGLU116 a subset of retained cMANA peptides elicited a MANA-specific clonal T cell expansion (Supplementary Table S9 ). For gained cMANAs, we were only able to evaluate case CGLU116 as this was the only one for which additional PBMCs were available. These analyses identified a small fraction of gained cMANA peptides (30% of peptides tested) that elicited a MANA-specific clonal T cell expansion in autologous T cell cultures from this patient (Supplementary Table S9 ).
These findings indicate that patient-derived T cells recognized the eliminated neoantigens and suggest that these neoantigens were relevant targets for the achievement of initial therapeutic response to checkpoint blockade.
Conceptually, there could be two mechanisms of neoantigen loss in resistant tumors. The first is through the immune elimination of neoantigen-containing tumor cells that represent a subset of the tumor cell population, followed by subsequent outgrowth of the remaining cells. The second is through the acquisition of one or more genetic events in a tumor cell that results in neoantigen loss, followed by selection and expansion of the resistant clone. The first mechanism would only be possible for subclonal neoantigens while the second could serve as a mechanism of resistance for both clonal and subclonal alterations. To evaluate the contribution of these mechanisms to the loss of neoantigens, we analyzed the tumors both before and after therapy using the SCHISM pipeline (22) , and incorporated mutation frequency, tumor purity, and copy number variation to infer the fraction of cells containing a specific mutation (mutation cellularity) (see Methods, Supplementary Tables S10-S13). Through these approaches we estimated that alterations with a mutation cellularity >0.75 were present in all tumor cells
Research. (truncal) while the remainder were considered to be subclonal. Consistent with our predictions, we observed both mechanisms of neoantigen elimination: loss of 3 truncal changes and elimination of 38 subclonal cMANAs at the time of emergence of resistance (Supplementary Tables S10-S14). Analysis of genome-wide structural alterations revealed that all clonal neoantigens were lost through genetic events involving chromosomal deletions and loss of heterozygosity (LOH) (Figure 3, Supplementary Figures S7-S10 , Supplementary Tables S10-S14).
Subclonal neoantigens were lost either by LOH or through elimination of tumor subclones. Both truncal and subclonal changes were among the eliminated neoantigens that were functionally validated (Supplementary Table S8 ).
To evaluate the impact of changes in neoantigen landscape on cytotoxic T cell receptor repertoire, we analyzed serially collected PBMCs, prior to immunotherapy initiation, at clinical response, and at resistance for patients CGLU117 and CGLU127 and at response and disease progression for patient CGLU161 (Supplementary Table S15 ). We hypothesized that loss of neoantigens would lead to a decrease in clonality of cytotoxic TCR clonotypes, thus reflecting tumor immune evasion at the time of emergence of resistance. For patients CGLU127 and CGLU117, we observed peripheral T cell expansion of a subset of the top 100 most frequent intratumoral clones, with the most frequent clones reaching a 44-and 25-fold increase in abundance in the blood at the time of response, respectively, followed by a decrease to pretreatment levels at the time of resistance ( Figure 3C and Supplementary Figure S11 ). For patient CGLU117, this observation was consistent with the fact that CD8+ immune density did not change significantly in pre-treatment and resistant tumors ( Figure 3F -G, Supplementary Table S16). Importantly, for patient CGLU127, the TCR clonotype specific to the functionally validated eliminated neoantigen encoding the 603K>T alteration in ANKRD12 was among the top 20 circulating TCR clones, demonstrating a similar clonal expansion at the time of response and reduction at the time of emergence of resistance. Similarly, for patient CGLU161, the TCR clone that expanded after stimulation with the EP300 1250C>Y MANA was one of the top 3 clonotypes observed in peripheral blood at the time of response and its frequency decreased upon emergence of resistance (Supplementary Figure S11) . For this case, a decrease in abundance was also observed for the predominant peripheral TCR clonotypes that were also Figure S11) . As a comparison, such decreases in TCR frequencies were not observed in a NSCLC patient with durable response to PD-1 blockade and no change in intratumoral TCR frequencies was seen in a NSCLC patient with primary resistance to PD-1 blockade (Supplementary Figure S12) . Taken together, these observations suggest that TCR expansion may be both a useful measure of response to checkpoint blockade as well as an indicator of acquired therapeutic resistance through neoantigen loss.
Discussion
Despite the compelling and increased durability of clinical efficacy of immune checkpoint inhibitors relative to chemotherapy or oncogene-targeted therapy, the majority of patients eventually experience therapeutic resistance after an initial response to these therapies.
Through our comprehensive genomic analyses, we have identified changes in the genomic landscape of tumors during immune checkpoint blockade. These analyses show that emergence of acquired resistance is associated with loss of mutations encoding for putative tumor-specific neoantigens, both through elimination of tumor subclones or chromosomal loss of truncal alterations. Using a new approach to assess neoantigen reactivity by T cells, we found that some of these eliminated mutations encoded peptides recognized by T cells in the peripheral circulation of the respective patients. Given that the anti-tumor efficacy of checkpoint blockade likely involves release of endogenous T cell responses to tumor antigens generated by coding mutations, our findings are consistent with a mechanism of acquired resistance to immune checkpoint blockade that involves therapy-induced immune editing of MANAs.
Acquisition of somatic resistance mutations is a common mechanism of therapeutic resistance to targeted therapies (23) . However, elimination of genomic alterations and more specifically loss of somatic mutations through subsequent genetic events is uncommon in the context of natural tumor evolution or therapeutic resistance (24) (25) (26) . Elimination of mutation associated antigens by a T-cell-dependent immunoselection process has been proposed as a mechanism of cancer immunoediting in mouse models (27) and melanoma after adoptive T cell transfer (28) but the evolution of neoantigen loss as an escape mechanism under the selective pressure of immune checkpoint blockade in lung cancer has not been previously studied. We found that in tumor samples analyzed at the time of acquired resistance the majority of eliminated mutations were in genes typically expressed at high levels in lung cancer and encoded for neoantigens that were predicted to either confer high affinity MHC binding or affect TCR contact residues. Eliminated neoantigens elicited a specific T cell expansion and it is conceivable that the identified neoantigens eliminated at the time of emergence of resistance were immunodominant (29) . In the setting of viral infections, it is common that the immune system focuses on a limited number of dominant viral epitopes and loss of these epitopes is a common mechanism of viral persistence and immune evasion. The determination of the overall role of loss of dominant tumor MANAs in acquired resistance to immunotherapy with checkpoint blockade will require extensive evaluation of MANA-specific immune responses in larger numbers of patients at varying times during response and relapse.
For these patients, we examined a variety of other mechanisms that have been proposed in the development of resistance to immunotherapies (30) . We did not observe any differences in PD- While larger studies will be required to study the full spectrum of therapeutic resistance to immunotherapy, our findings provide insights into the relatively rapid dynamics of neoantigen gains and losses during therapy and reveal a potential mechanism of resistance for at least a fraction of these patients. One future area of investigation for patients with metastatic disease will be a comprehensive analysis of the evolving neoantigen landscape among different 
Whole-exome sequencing, neoantigen prediction and T cell receptor sequencing
Whole exome sequencing was performed on the pre-treatment and post-progression tumor and matched normal samples. Tumor samples underwent pathological review for confirmation of lung cancer diagnosis and assessment of tumor purity. Slides from each FFPE block were macrodissected to remove contaminating normal tissue. Matched normal samples were provided as peripheral blood. DNA was extracted from patients' tumors and matched peripheral blood using the Qiagen DNA FFPE and Qiagen DNA blood mini kit respectively (Qiagen, CA). Fragmented genomic DNA from tumor and normal samples was used for Illumina TruSeq library construction (Illumina, San Diego, CA) and exonic regions were captured in solution using the Agilent SureSelect v.4 kit (Agilent, Santa Clara, CA) according to the manufacturers' instructions as previously described (16, 23, 35) . Paired-end sequencing, resulting in 100 bases from each end of the fragments for the exome libraries was performed using Illumina HiSeq 2000/2500 instrumentation (Illumina, San Diego, CA). The mean depth of coverage for the pre-treatment and resistant tumors was 214x and 217x respectively, allowing us to identify sequence alterations and copy number changes in >20,000 genes (Supplementary Table S2 ).
Primary processing of next-generation sequencing data and identification of putative somatic mutations
Research. Somatic mutations were identified using the VariantDx custom software for identifying mutations in matched tumor and normal samples (16) . Prior to mutation calling, primary processing of sequence data for both tumor and normal samples were performed using Illumina CASAVA software (version 1.8), including masking of adapter sequences. Sequence reads were aligned against the human reference genome (version hg19) using ELAND with additional realignment of select regions using the Needleman-Wunsch method (36) . Candidate somatic mutations, consisting of point mutations, insertions, deletions as well as copy number changes were then identified using VariantDx across the whole exome. VariantDx examines sequence alignments of tumor samples against a matched normal while applying filters to exclude alignment and sequencing artifacts. In brief, an alignment filter was applied to exclude quality failed reads, unpaired reads, and poorly mapped reads in the tumor. A base quality filter was applied to limit inclusion of bases with reported Phred quality score > 30 for the tumor and > 20 for the normal. A mutation in the pre or post treatment tumor samples was identified as a candidate somatic mutation only when (1) distinct paired reads contained the mutation in the tumor; (2) the fraction of distinct paired reads containing a particular mutation in the tumor was at least 10% of the total distinct read pairs and (3) the mismatched base was not present in >1% of the reads in the matched normal sample as well as not present in a custom database of common germline variants derived from dbSNP and (4) the position was covered in both the tumor and normal. Mutations arising from misplaced genome alignments, including paralogous sequences, were identified and excluded by searching the reference genome. To validate our mutation detection approach, we investigated whether the gained and lost genomic alterations derived from single base substitutions were also detected by the MuTect method (37) . We found that 98% of the eliminated and 99% of the gained genomic alterations identified by our pipeline were also detected by MuTect, providing independent confirmation of our methodology. To ensure that the mutations that were absent in individual tumor specimens were not simply due to low coverage, we required that each mutated base be sequenced at a level that was at least 20% of the average sequence coverage of that sample. Alterations in cases where both tumor samples had tumor purity <50% (CGLU116) were analyzed with the above criteria except that the minimum fraction of distinct reads was 5% as adjusting the Given the high polymorphism of the HLA loci which can prevent appropriate alignment of sequencing reads to the reference genome, we performed a separate bioinformatic analysis using POLYSOLVER to independently detect somatic Class I HLA mutations (14) . These analyses confirmed that there were no somatic HLA mutations as originally determined by our whole exome sequencing analysis pipeline.
Neoantigen Predictions
Research. To assess the immunogenicity of somatic mutations, exome data combined with each individual patient's MHC class I haplotype were applied in a neoantigen prediction platform that evaluates binding of somatic peptides to class I MHC, antigen processing, self-similarity and gene expression. Detected somatic mutations, consisting of nonsynonymous single base substitutions, insertions and deletions, were evaluated for putative neoantigens using the ImmunoSelect-R pipeline (Personal Genome Diagnostics, Baltimore, MD). For single base substitutions, ImmunoSelect-R performs a comprehensive assessment of paired somatic and wild type peptides 8-11 amino acids in length at every position surrounding a somatic mutation.
In the case of frameshifts, all peptides 8-11 amino acids encompassing the new protein sequence resulting from the frameshift alteration were considered. To accurately infer a patient's germline HLA 4-digit allele genotype, whole-exome-sequencing data from paired tumor/normal samples were first aligned to a reference allele set, which was then formulated as an integer linear programming optimization procedure to generate a final genotype (40) . The HLA genotype served as input to netMHCpan to predict the MHC class I binding potential of each somatic and wild-type peptide (IC 50 nM), with each peptide classified as a strong binder (SB), weak binder (WB) or non-binder (NB) (41) (42) (43) . Peptides were further evaluated for antigen processing by netCTLpan (44) and were classified as cytotoxic T lymphocyte epitopes (E) or nonepitopes (NA). Paired somatic and wild-type peptides were assessed for self-similarity based on MHC class I binding affinity (45) . Neoantigen candidates meeting an IC 50 affinity < 5000nM were subsequently ranked based on MHC binding and T-cell epitope classifications. Tumor-associated expression levels derived from TCGA were used to generate a final ranking of candidate immunogenic peptides. Anchor and auxiliary anchor residues for mutant peptides-HLA class I allele pairs were evaluated by the SYFPEITHI online tool (46) . To generate Supplementary Table   S6 we filtered the neoantigen predictions by applying a 500nM MHC affinity threshold and reduced the redundancy by selecting the strongest binding neoepitope specific to an HLA allele with known binding motifs in SYFPEITHI.
Somatic copy number analysis
Research. Genome-wide copy number profile of each tumor sample was derived by comparing the abundance of aligned reads to each region between tumor and matched normal samples using the CNVkit method (47). CNVkit enables inference and visualization of copy number aberrations from sequencing data. The method uses sequencing reads mapped to the exome, as well as non-specifically captured reads, and corrects the sequencing depth profile with respect to three sources of bias: GC-content, capture target size, and regions containing sequence repeats. We derived a preliminary estimate of genome-wide copy number profile of each tumor sample as quantified by log2 ratio of reads between tumor and matched normal. Next we estimated the tumor purity by cross-analysis of these log2 ratio values and minor allele frequency of germline heterozygous variants. The estimated tumor purity ( ) was used to convert the observed raw log2 ratio ( ) to tumor copy number ( ), correcting for contribution of normal cell copy number ( ) as follows:
The corresponding tumor copy number values were rounded to closest integer levels to yield the final somatic copy number profile.
Tumor purity estimation
Normal cell contamination is one of the factors complicating the analysis of somatic alterations in solid tumors (48) . To estimate the purity of each tumor sample, we extended the framework of SCHISM 1.1.1 (22) to cross-analyze the preliminary somatic copy number profile, and the minor allele frequency distribution of germline heterozygous single nucleotide polymorphisms (SNPs) along the genome. In each tumor sample, we selected a candidate subset of chromosomes or chromosome arms where there was a clear deviation of the minor allele frequencies from the expected value of 0.5, and log2 ratio of read counts indicated one copy loss by visual inspection (Supplementary Table S17 ). The expected minor allele frequency of germline heterozygous SNPs was calculated as
Research. 
where is the proportion of cancer cells in the sequenced tumor bulk (tumor purity), and and are the number of copies of minor allele present in tumor and normal cells, respectively. In regions of one copy loss, the minor allele is absent in tumor cells ( = 0) and present in one copy in normal cells ( = 1), tumor copy number is one ( = 1) and normal copy number is two ( = 2), therefore:
We identified the mode of minor allele frequency in each such region and estimated the tumor purity as the average purity values estimated for the analyzed regions. To validate the accuracy of our method to estimate tumor purity we compared tumor purity estimates derived by SCHISM to four methods of estimating purity: 1) Pathology review, 2) Mutation allele frequency, 3) PyLOH (49) and 4) Sequenza (50) (Supplementary Table S18 Figure S15) . On average, results from PyLOH had the largest difference (as measured by root mean squared error) with those of other methods, and the smallest dynamic range. Of the three copy number based methods, our method had the smallest root mean squared error when compared to the mutation-based approach.
Genome-wide analysis of allelic imbalance
In each tumor sample, we examined evidence for allelic imbalance in genomic regions surrounding somatic mutations. For each mutation, we compared the minor allele frequency of 20 closest germline heterozygous SNPs with coverage of at least 10 reads between tumor and matched normal sample using a 1-sided t-test. The p-values were corrected for multiple hypothesis testing using 
(FDR) less than or equal to 0.05 and a difference of at least 0.10 between the average minor allele frequencies of tumor and normal were marked as harboring allelic imbalance.
Somatic mutation cellularity estimation
Estimating the fraction of cancer cells harboring each somatic mutation (mutation cellularity) is central to reconstruction of subclone hierarchies and tumor evolution. We used an extension of the framework in SCHISM-1.1.1 (22) to derive point estimates and confidence intervals of mutation cellularities as follows: For each mutation, the expected value of variant allele frequency was determined by tumor sample purity , tumor copy number , normal copy number , mutation cellularity and mutation multiplicity . Mutation multiplicity refers the number of mutant alleles present in tumor cells harboring the mutation. The expected variant allele frequency was calculated as:
For each mutation, we derived a cellularity estimate at each possible multiplicity values (in absence of allele specific tumor copy number, ∈ {1, … , } ) as follows. Given a multiplicity value , we found the expected variant allele frequency for each value of cellularity in = {0.00, 0.01, … ,1.00}. Next, we found the binomial likelihood of observing variant reads out of total reads covering the mutation where success probability is set to . We normalized these likelihood values to sum to one, and derived the maximum likelihood estimate of cellularity and the 95% confidence interval using this normalized likelihood distribution over .
We selected the level of multiplicity for each mutation in each sample as follows: The multiplicity for mutations with tumor copy number of 1 is 1. Mutations with tumor copy number of 2 and outside regions with allelic imbalance are assumed to have multiplicity of 1.
Mutations with tumor copy number of 2, and in regions with allelic imbalance are assumed to have multiplicity of 2. For mutations that are lost where allelic imbalance was absent in pre- treatment sample and was present in post-treatment sample, multiplicity is assumed to be 1.
Mutations absent in pre-treatment sample and in regions with constant tumor copy number between pre-and post-treatment samples have multiplicity of 1. Finally, for mutations lost where tumor copy number changes from 3 in pre-treatment to 2 in post-treatment sample, and allelic imbalance only present in pre-treatment sample, multiplicity is assigned to 1. For mutations where multiplicity (and cellularity) could not be determined using the above approach, we used a secondary method. This involves clustering above mutations to identify groups of mutations with similar cellularity across all available samples. For each unclassified mutation, the unresolved cellularity (and multiplicity) values are selected to minimize the distance to the closest mutation cluster. A cellularity > 0.75 was used to differentiate truncal from subclonal mutations.
Stimulation and expansion of MANA-reactive T cells
Functional assays of peptide stimulated T cell expansion were performed for cases CGLU116, CGLU127 and CGLU161. On day 0, T cells were isolated from PBMC by negative selection (EasySep; STEMCELL Technologies). The T cell-negative fraction was gamma irradiated (3,000 rads) and co-cultured with an equal number of negatively-selected T cells in culture media (AIM V with 50μg/ml gentamicin) with 1μg/ml relevant peptide (Sigma-Aldrich, St. Louis, MO) and supplemented with IL-7 (25 ng/ml; Miltenyi, Auburn, CA) and IL-15 (25 ng/ml; PeproTech, Rocky Hill, NJ). IL-2 (10 IU/ml; Chiron, Emeryville, CA) was added to the cultures on day 1. On day 3, half the media was replaced with fresh culture media containing the same concentrations of IL-2, IL-7, and IL-15 used previously. On day 7, half the media was replaced with fresh culture media containing 20 IU/ml IL-2 and 25 ng/ml IL-7 and IL-15. On day 9, half the media was Table S15 ).
Immunohistochemistry and Interpretation of PD-L1 and CD8 staining
Immunohistochemistry for PD-L1 was performed using the PD-L1 IHC 22C3 pharmDx assay kit (Dako, CA). In brief, slides were deparaffinized with xylene and rehydrated with ethanol.
Antigen retrieval was performed using citrate buffer (pH=6) at a temperature of 97 °C for Table   S16 ). CD8 expression was evaluated in pre-treatment and post-progression tissue specimens for CLGU117 ( Figure 3 ) and in post-progression specimens for CGLU116 and CGLU161
(Supplementary Figure S16) given limited tissue availability for the remaining cases.
Statistical analyses
Somatic mutations found to harbor at least one candidate neoantigen were utilized to compare features of immunogenicity between those eliminated and those shared or gained after treatment across the four patients. Given a specific binding threshold (IC 50 ), mutations that generated neoantigens were characterized for features including minimum predicted IC 50 , average predicted affinity, the number of strong binder classifications and corresponding gene expression. To reduce redundancy, somatic mutations with multiple peptides satisfying the IC 50 threshold were represented by their average value for downstream statistical comparisons of lost and shared/gained groups. The student's T test was applied to compare mean predicted MHC affinities between lost and gained, and lost and retained cMANAs using both a 50nM and 
